Results 81 to 90 of about 5,265 (145)

Sofosbuvir [PDF]

Reactions Weekly, 2020
  +5 more sources

Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder

Pregnancy, Volume 2, Issue 5, September 2026.
Abstract Introduction In the past decade, hepatitis C virus (HCV) infections among pregnant women increased dramatically in the United States, rising in parallel with the opioid crisis and increasing the number of children at risk for HCV. People with HCV infection that remains untreated are also at increased risk of cirrhosis, liver cancer, and death.
Lucas Gosdin, Kathryn Miele, Shin Y. Kim, Marcela C. Smid, Julie H. Shakib, Judette M. Louis, Tanner Wright, Neil S. Seligman, Carrie Irvine, Pilar M. Sanjuan, Lawrence Leeman, Michelle L. Henninger, Autumn Davidson, Elisha M. Wachman, Kara M. Rood, Anna Bartholomew, Suzanne Gilboa, Kate R. Woodworth, Van T. Tong, Lakshmi Panagiotakopoulos   +19 more
wiley   +1 more source

The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C

, 2015
Hepatitis C virus (HCV) infection is a worldwide health problem, whose management has been revolutionized after the availability of sofosbuvir, a direct-acting antiviral (DAAs). Sofosbuvir is a HCV NS5B polymerase inhibitor.
ZAPPULO, EMANUELA, BUONOMO, ANTONIO RICCARDO, MARAOLO, ALBERTO ENRICO, GENTILE, Ivan, BORGIA, GUGLIELMO   +4 more
core   +1 more source

The effects of sofosbuvir-based treatment of hepatitis C virus on patients with chronic obstructive pulmonary disease

Egyptian Journal of Chest Disease and Tuberculosis, 2020
Background To date, no sufficient reports have studied the effects of sofosbuvir-based hepatitis C virus (HCV) treatment regimens on chronic obstructive pulmonary disease(COPD) exacerbation.
Ahmad Abbas, Ahmed A Abdelmoaty, Ahmed M El-Gebaly, Maha E Alsadik   +3 more
doaj   +1 more source

Effect of sofosbuvir on QT interval and other electrocardiography (ECG) findings in patients with HCV related decompase cirrhosis

The Turkish Journal of Gastroenterology, 2019
Effect of sofosbuvir on QT interval and other electrocardiography (ECG) findings in patients with HCV related decompase cirrhosis The sofosbuvir is a direct acting antiviral agent commonly used nowadays in patients with decompensated cirrhosis.
Mehmet Demir
doaj   +1 more source

Sofosbuvir-based regimens against an “easy” villain: HCV genotype 2

, 2017
Sofosbuvir-based regimens against an “easy” villain: HCV genotype
Angarano, Gioacchino, Annalisa Saracino, Bruno, Giuseppe, Giuseppe Bruno, Milella, Michele, Saracino, Annalisa, Gioacchino Angarano, Michele Milella   +7 more
core   +1 more source

Changing the face of hepatitis C management – the design and development of sofosbuvir

Drug Design, Development and Therapy, 2015
Bennett C Noell,* Siddesh V Besur,* Andrew S deLemos Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, Charlotte, NC, USA *These authors contributed equally to this work Abstract: The availability of
Noell BC, Besur SV, deLemos AS
doaj  

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

, 2018
Ossama A Ahmed,1 Hany H Kaisar,1 Rehab Badawi,2 Nehad Hawash,2 Hossam Samir,1 Sherif ST Shabana,1 Mohamed Hassan A Fouad,1 Fatma H Rizk,3 Samy A Khodeir,4 Sherief Abd-Elsalam2 1Department of Internal Medicine, Faculty of Medicine, Ain Shams University ...
Shabana SST, Hawash N, Kaisar HH, Khodeir SA, Abd-Elsalam S, Ahmed OA, Samir H, Badawi R, Fouad MHA, Rizk FH   +9 more
core  

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Biology, 2017
The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2.
Tatsuo Kanda, Masato Nakamura, Shin Yasui, Yuki Haga, Akinobu Tawada, Eiichiro Suzuki, Yoshihiko Ooka, Koji Takahashi, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Makoto Arai, Fumio Imazeki, Osamu Yokosuka   +13 more
doaj   +1 more source

The cost of treatment coverage with sofosbuvir or ledipasvir/sofosbuvir of different proportions of patients with viraemic HCV infection (for point estimates and uncertainty intervals) as a proportion of PPP-adjusted current total pharmaceutical expenditure.

, 2016
The cost of treatment coverage with sofosbuvir or ledipasvir/sofosbuvir of different proportions of patients with viraemic HCV infection (for point estimates and uncertainty intervals) as a proportion of PPP-adjusted current total pharmaceutical ...
Peter Beyer (21528), Kees de Joncheere (3166164), Stefan Wiktor (3166158), Kiu Tay-Teo (3166161), Swathi Iyengar (3166167), Sabine Vogler (3131850), Suzanne Hill (160643)   +6 more
core   +1 more source